| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.02 | 1.03▼ | 1.03▼ | 1.02▲ | 1.05▼ |
| MA10 | 1.03▼ | 1.04▼ | 1.04▼ | 1.03▼ | 1.18▼ |
| MA20 | 1.04▼ | 1.04▼ | 1.04▼ | 1.08▼ | 1.33▼ |
| MA50 | 1.05▼ | 1.09▼ | 1.11▼ | 1.25▼ | 1.83▼ |
| MA100 | 1.12▼ | 1.17▼ | 1.20▼ | 1.38▼ | 1.99▼ |
| MA200 | 1.20▼ | 1.29▼ | 1.32▼ | 1.77▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | 0.002▲ | 0.004▲ | 0.006▲ | -0.017▼ |
| RSI | 31.438▼ | 36.318▼ | 37.440▼ | 35.847▼ | 33.150▼ |
| STOCH | 0.000▼ | 8.333▼ | 50.833 | 48.418 | 7.826▼ |
| WILL %R | -100.000▼ | -100.000▼ | -60.000 | -66.622 | -89.286▼ |
| CCI | -102.600▼ | -131.455▼ | -39.092 | -39.519 | -106.967▼ |
|
Friday, October 16, 2026 08:20 AM
ImmunityBio has secured early FDA label expansion for Anktiva in BCG-unresponsive NMIBC. Check out why IBRX stock is a hold.
|
|
Wednesday, October 14, 2026 01:18 PM
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® ...
|
|
Thursday, September 03, 2026 07:54 AM
ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/10/26 | 1.025 | 1.025 | 1.025 | 1.025 | 70 |
| 16/10/26 | 1.0301 | 1.0301 | 1.02 | 1.02 | 5,409 |
| 15/10/26 | 1.015 | 1.035 | 1.015 | 1.03 | 4,503 |
| 14/10/26 | 1.00 | 1.02 | 0.9977 | 1.00 | 26,811 |
| 13/10/26 | 1.01 | 1.04 | 0.9999 | 1.02 | 10,157 |
| 12/10/26 | 1.03 | 1.035 | 1.01 | 1.03 | 18,909 |
| 09/10/26 | 1.07 | 1.07 | 1.0321 | 1.05 | 3,020 |
| 08/10/26 | 0.99 | 1.06 | 0.95 | 1.045 | 30,596 |
| 07/10/26 | 1.03 | 1.0352 | 0.9701 | 0.9907 | 22,921 |
| 06/10/26 | 1.03 | 1.07 | 1.025 | 1.05 | 6,787 |
|
|
||||
|
|
||||
|
|